Episode 1 of our special two-part Conversations in Lung Cancer Research series explores one of the most significant changes to immunotherapy access in Australia. In this episode, the panel discusses the landmark PBS listing of ipilimumab and nivolumab,
"So the broadening of the listing of ipilimumab and nivolumab to cover immunotherapy sensitive, advanced, or metastatic disease indications was made available from the 1st of March this year in Australia. And as a global first, removed that tumor type siloing, allowing prescribing based on clinical judgment and best available evidence for the patient we have in front of us."
💬 Discussion
Episode 1 of our special two-part Conversations in Lung Cancer Research series explores one of the most significant changes to immunotherapy access in Australia. In this episode, the panel discusses the landmark PBS listing of ipilimumab and nivolumab,